Shimizu Takahiko, Matsuoka Yasuji, Shirasawa Takuji
Research Team for Molecular Biomarkers, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Biol Pharm Bull. 2005 Sep;28(9):1590-6. doi: 10.1248/bpb.28.1590.
Isomerization of L-aspartate and deamidation of L-asparagine in proteins or peptides dominantly give rise to L-isoaspartate by a non-enzymatic reaction via succinimide as a intermediate under physiological conditions. Isoaspartates have been identified in a variety of cellular proteins in vivo as well as pathologically deposited proteins in neurodegenerative brain tissue. We described here that the formation of isoaspartate is enhanced in amyloid-beta (Abeta) peptides in Alzheimer's disease (AD). Specific antibodies recognizing isoaspartate of Abeta revealed that isomerized Abeta peptides were deposited in senile plaques as well as amyloid-bearing vessels. Moreover, it was revealed that Abeta peptides, isomerized at position 7 or 23, were differentially deposited in senile plaques and vascular amyloids in AD brains. In vitro experiments showed that the modification at position 23 greatly enhanced the aggregation of Abeta. Furthermore, systematic proline substitution analyses revealed that the beta-turn structure at positions 22 and 23 of Abeta42 plays a crucial role in the aggregation and neurotoxicity of Abeta peptides. It is suggested that spontaneous isomerization at position 23 induces the conformational change to form a beta-turn at position 23, which plays a pathogenic role in the deposition of Abeta peptides in sporadic AD. Protein L-isoaspartyl methyltransferase (PIMT) is a putative protein repair enzyme, which converts L-isoaspartyl residues in damaged proteins to normal L-aspartyl residues. PIMT-deficient mice manifested neurodegenerative changes concomitant with the accumulation of L-isoaspartate in the brain. We discuss here the pathological implications of the formation of isoaspartate in damaged proteins during neurodegeneration in model mice and AD.
在生理条件下,蛋白质或肽中的L-天冬氨酸异构化和L-天冬酰胺脱酰胺主要通过琥珀酰亚胺作为中间体的非酶促反应产生L-异天冬氨酸。异天冬氨酸已在体内多种细胞蛋白以及神经退行性脑组织中的病理性沉积蛋白中被鉴定出来。我们在此描述,在阿尔茨海默病(AD)的β-淀粉样蛋白(Aβ)肽中,异天冬氨酸的形成有所增强。识别Aβ异天冬氨酸的特异性抗体显示,异构化的Aβ肽沉积在老年斑以及含淀粉样蛋白的血管中。此外,研究发现,在第7位或第23位异构化的Aβ肽在AD大脑的老年斑和血管淀粉样蛋白中存在差异沉积。体外实验表明,第23位的修饰极大地增强了Aβ的聚集。此外,系统性的脯氨酸替代分析表明,Aβ42第22位和第23位的β-转角结构在Aβ肽的聚集和神经毒性中起关键作用。提示第23位的自发异构化诱导构象变化,在第23位形成β-转角,这在散发性AD中Aβ肽的沉积中起致病作用。蛋白质L-异天冬氨酰甲基转移酶(PIMT)是一种假定的蛋白质修复酶,可将受损蛋白中的L-异天冬氨酰残基转化为正常的L-天冬氨酰残基。PIMT缺陷小鼠表现出神经退行性变化,同时大脑中L-异天冬氨酸积累。我们在此讨论模型小鼠和AD中神经退行性变期间受损蛋白中异天冬氨酸形成的病理意义。